Veterinary Orthopedics Market Size Worth $752.96 Million by 2026

The global veterinary orthopedics market size is expected to reach USD 752.96 million by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 8.4% during the forecast period. Growing incidence of pet obesity and arthritis is expected to drive the growth. Moreover, increasing number of veterinary practitioners coupled with rapid technological advancements in veterinary devices are the major factors driving the market. Moreover, high prevalence of pet obesity increases the risk of osteoarthritis, which is expected to propel the market growth in near future.

Moreover, increasing number of veterinary hospitals and surgical procedures are further fueling the veterinary orthopedics market. According to the AAPA report, in U.S. around 20.8 million dogs went through surgery in 2016 and among them 5.8 million had very painful surgeries. The aforementioned reasons are expected to further boost the market growth. For instance, in July 2018, B. Braun Vet Care entered into an agreement with CP Medical to market B. Braun’s veterinary infusion therapy product in U.S. and Canada.

North America held the dominant market share in 2018, due to the favorable insurance policies and new product developments. For instance, In December 2015, Universal Medical Systems, Inc. introduced Computed Tomography (CT) system in partnership with Equine 4DDI which is used for whole-body scans of moving and standing horses.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/veterinary-orthopedics-market

Further key findings from the report suggest:

Increasing prevalence of osteoarthritis is anticipated to create growth opportunities in the veterinary orthopedics market
Implants segment is projected to hold the largest market share over the forecast period, owing to its increased demand
Plate segment is expected to exhibit lucrative growth, owing to multipurpose use of the product during surgeries
The others segment which includes TPLO and TTA implants, held the largest revenue share in 2018. These surgical procedures have proved to be effective, where other alternative methods have failed
Asia Pacific is anticipated to witness lucrative growth due to rising pet adoption coupled with growing economy, especially in Japan and India
Some of the key companies are Veterinary orthopedic implants; B. Braun Vet Care GmbH; KYON Pharma Inc.; and Surgical holdings, among others

FISH Imaging Systems Market Worth $1.4 Billion By 2025

The global fluorescence in situ hybridization imaging systems market size is expected to reach USD 1.4 billion by 2025, at a CAGR of 8.1% according to a new report by Grand View Research, Inc. Increasing R&D investments pertaining to in vitro diagnostics are expected to drive the Fluorescence In Situ Hybridization (FISH) imaging systems market. The presence of government organizations, such as the European Diagnostic Manufacturers Association that focuses on the development and growth of the in vitro diagnostics market in Europe, is also contributing to growth.

Furthermore, FISH imaging systems are gaining popularity in diagnostics for the determination of suspected diseases caused by pathogens or bacteria. Increasing incidence of genetic diseases, such as lymphoma, solid tumors, leukemia, autism, and other developmental syndromes, is also expected to boost adoption. Growing penetration of fluoroscopy, microscopes, illuminators, and CCD cameras in testing for infectious diseases is expanding growth opportunities for these systems. Increasing prevalence of diseases with chromosomal aberrations, such as cancer and genetic abnormalities, as well as unmet diagnostic & clinical needs in developing countries, is anticipated to drive the market.

Moreover, increasing demand for rapid, sensitive, & accurate diagnostic techniques for validation of diseases, coupled with rising awareness, increase in healthcare expenditure, and extensive R&D for the development of novel imaging systems are also expected to drive growth over the forecast period.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/fluorescence-in-situ-hybridization-fish-imaging-systems-market

Further Key Findings From the Report Suggest:

Instruments held the largest market, whereas FISH imaging services are expected to grow at the fastest rate during the forecast period
At present, the market penetration of FISH imaging in cancer diagnostics is very high, hence the diagnostic laboratories segment accounted for larger revenues
Cancer diagnosis held the largest revenue share owing to increasing incidence of cancer, thus fueling the adoption of FISH imaging systems
Among end-use segments, companion diagnostics is expected to witness faster growth than research and diagnostic segments
Diagnostic laboratories held the dominant position in 2016 as these systems are predominantly used in various clinical studies for visualization of precancerous lesions in cervical cancer, assessing the risk of human papillomavirus, and for detection of leukemia, myelodysplastic syndrome, multiple myeloma, & chromosomal abnormalities
North America held the largest revenue share owing to extensive adoption of these solutions in research and development across this region
Asia Pacific is anticipated to exhibit lucrative CAGR over the forecast period due to the increase in investments by manufacturers & governments, supportive government initiatives in the biotechnology sector, and the presence of a large number of untapped opportunities
The industry is highly competitive with a limited number of players holding a majority of the overall revenues. Some of the most notable market participants are Thermo Fisher Scientific, Inc., and General Electric Company. They account for a considerable share of the industry

Blood Transfusion Diagnostics Market Size Worth $5.8 Billion By 2027

The global blood transfusion diagnostics market size is expected to reach a value of USD 5.8 billion by 2027 registering a CAGR of 6.6%, according to a new report by Grand View Research, Inc. Growing prevalence of chronic diseases, such as anemia, sickle cell disease, hemophilia, cancer, and kidney disease, is significantly driving the market growth. According to the Sickle Cell Disease Coalition statistics, globally, the number of sickle cell disease cases is projected to increase by around 30% by 2050.According to NCBI statistics, liver diseases accounts for around 2 million deaths each year globally. Blood transfusion is crucial for patients with such chronic diseases, as it allows to exchange the diseased cells with the healthy RBCs without disrupting the blood viscosity.

Female transfused holding a tablet computer in hospital ward

According to the National Blood Transfusion Service (NBTS) database, a total of 60,236 donor screening was done between 2010 and 2016 at the National Blood Transfusion Center (NBTC), Eritrea. Among them, at least 3.6% of the donated blood showed positive results for TTI and 0.1% showed positive results for multiple infections. Some of the chronic infectious diseases, such as hepatitis B, hepatitis C, HIV, and syphilis, create the need for accurate donor screening, thus further driving the market growth of diagnostics. Transfusion is commonly used in cases of trauma, road accidents, surgeries, childbirth, and gastrointestinal bleeding to replace major blood losses.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/blood-transfusion-diagnostics-market

Further key findings from the report suggest:

Reagents and kits is expected to be the largest as well as the fastest-growing product segment from 2020 to 2027
The disease screening segment is projected to register the fastest CAGR over the forecast period
According to the WHO, screening of donated blood for detecting transfusion transmissible infections, such as hepatitis B & C and HIV, should be mandatory
The hospitals end-use segment is estimated to account for the second largest market share by 2027 on account of rising instances of Pretransfusion therapies being performed in hospitals as the therapy requires cross-matching tests between the donor and recipient
Asia Pacific is projected to be the fastest-growing regional market due to rising geriatric population, especially in China and Japan

Protein Purification And Isolation Market Worth $11.2 Billion By 2027

The global protein purification and isolation market size is expected to reach USD 11.2 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 8.3% over the forecast period. An increase in technological advancements and investments for the development of structure-based drugs by both private and public research organizations are driving the demand for protein purification and isolation products.

Rising demand for the development of single-use products for purification due to the increasing need to classify novel protein-based ligands with high specificity and improved proteomics research is further driving the market growth. Another factor driving the adoption rate of protein purification techniques is the availability of an extensive range of innovative resins for various applications.

The key players operating in the market are Merck KGaA; Thermo Fisher Scientific; Qiagen; Sigma-Aldrich Co.; GE Healthcare; Agilent Technologies; Bio-Rad Laboratories, Inc.; Norgen Biotek Corporation; Abcam plc, and Promega Corporation. Market players are adopting strategies such as the expansion of product portfolio through R&D initiatives, mergers, acquisitions, and strategic collaborations to further strengthen their position in the market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/protein-purification-isolation-market

Further key findings from the report suggest:

The reagents segment is estimated to register a significant growth rate over the forecast period. This is attributed to its high usage in cell lysis and increased commercialization of advanced resins
On the basis of technology, chromatography emerged as the leading segment in 2019 owing to the availability of a varied range of products, enhanced results for complex protein purification, and high reliability
Drug screening is estimated to be the fastest-growing application segment over the forecast period owing to factors such as high efficacy and increasing R&D investments by manufacturers for the screening of novel drugs
Contract research organizations (CROs) are projected to witness a significant growth rate over the forecast period. This is attributed to increasing R&D investments and the growing number of preclinical trials outsourced by drug development firms
North America dominated the global protein purification and isolation market in 2019 owing to factors such as established research infrastructure, presence of major players, and technological advancements in the region
Asia Pacific is estimated to register the highest CAGR over the forecast period due to increasing economic stability, a growing number of CROs, and R&D activities in academic and research institutes.

Allergy Diagnostics & Therapeutics Market Worth $51.95 Billion By 2026

The global allergy diagnostics and therapeutics market size is expected to reach USD 51.95 billion by 2026 registering a CAGR of 6.3%, according to a new study by Grand View Research, Inc. Increasing prevalence of allergic conditions coupled with adoption of immunoassay as diagnostic test is expected to serve this market with lucrative growth opportunities. According to the report published by the World Allergy Journal in May 2014, around 300 million cases of asthma and 200 to 250 million cases of food allergies were reported. This number is expected to increase over the forecast period due to sedentary lifestyle and poor dietary habits.

cropped view of doctor in white coat and latex gloves holding marker pen near marked female hand

Rising industrial pollution, rapid urbanization in developing countries, and increasing Greenhouse Gas (GHG) concentrations are expected to result in increased prevalence of pollen induced respiratory disorder, thereby boosting the overall market growth over the forecast period. Emergence of technologically advanced products, such as MeDALL allergen-chip for allergy determination, is further expected to propel the market growth in the years to come.

The global market is highly competitive and is led by companies including Thermo Fisher Scientific, Omega Diagnostics, Siemens Healthcare, Stallergenes Greer, Lincoln Diagnostics, bioMerieux, HOB Biotech Group, Alcon Laboratories, Hycor Biomedical, and Hitachi Chemical Diagnostics. Most of the industry participants focus on the development of advanced products and technologies to gain competitive advantage. For instance, in March 2015, Stallergenes received approval for STG 320 in Japan, which is the first sublingual immunotherapy tablet used in the treatment of house dust mite allergy.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/allergy-diagnostic-market

Further key findings from the study suggest:

Instruments product segment is anticipated to witness the highest CAGR of 12.2% from 2019 to 2025 due to high demand for analyzers and laminators for allergy diagnostics
In vitro is expected to be the largest as well as fastest-growing test segment over the estimated period on account of rising demand for minimally invasive and allergen-specific tests
Antihistamines drug class led the allergy diagnostics and therapeutics market in 2018 due to its advantages, such as non sedating nature and minimum side effects with use of second generation antihistamines in allergy treatment
Immunotherapy vaccines is expected to register the maximum CAGR from 2019 to 2025 owing to extensive R&D in the field and advent of sublingual immunotherapy tablets in the treatment of allergic rhinitis
For instance, in April 2014, the U.S. FDA approved a five-grass pollen sublingual tablet (Ex-Oralair) by Stallergenes, which is used in the treatment of pollen allergy

Cell Expansion Market Worth $39.7 Billion By 2027

The global cell expansion market size is expected to reach USD 39.7 billion by 2027 registering a CAGR of 9.4%, according to a new report by Grand View Research, Inc. Cell expansion techniques are increasingly employed for the development of cellular and gene therapies from a single cord blood collection. These techniques can also be used for the expansion of stored Stem Cells (SCs) for the development of cancer therapies. Therefore, significant developments in cord blood SCs expansion technologies are expected to boost market growth.

Companies have made heavy investments for the expansion of tissue-engineered products and the development of biologics. For instance, in March 2019, Merck KGaA invested USD 168 million for the expansion of its biologics manufacturing facility in Switzerland. Such initiatives are expected to boost the demand for solutions required for biologic development, thereby leading to market growth.

Bioreactors are fundamental tools in this market. Extensive research studies related to the applications of bioreactor engineering approaches have led to the incorporation of novel culture technologies. Moreover, the combined use of automated bioreactors with the microcarrier technology leads to an efficient expansion and enrichment of the cancer SCs. As a result, these approaches have gained immense traction in this market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cell-expansion-market

Further key findings from the report suggest:

Broad portfolio of automated expansion systems along with improvements in bioreactor design for large-scale bioproduction results in the lucrative growth opportunity for instruments
The microbial cells segment is expected to witness the fastest growth rate owing to the implementation of high-throughput cultivation approaches and techniques that avoid the formation of biofilms
Biopharmaceuticals segment held the largest revenue share in 2019 due to growth in the demand for biosimilars, continuous R&D investments in biomanufacturing, and rise in the number of approvals for biologics
Asia Pacific is anticipated to grow at the maximum CAGR from 2020 to 2027 due to presence of several consortiums that focus on the evolving fields in the biomedical industry
For instance, in November 2019, the Cell & Gene Therapy Asia 2019 held in Japan focused on the evolving field of SCs for their deployment in pharmaceutical discovery and cellular therapies

Ultrasound Probe Disinfection Market Size Worth $700.3 Million By 2027

The global ultrasound probe disinfection market size is expected to reach USD 700.3 million by 2027 registering a CAGR of 9.4%, according to a new report by Grand View Research, Inc. Increasing number of ultrasound imaging procedures, rising prevalence of nosocomial infections, and technological advancements are the key driving factors for the global market.

Nosocomial or Hospital-acquired Infection (HAI) is an infection acquired in healthcare facilities, such as hospitals, clinics, rehabilitation facilities, and Ambulatory Surgery Centers (ASCs). Factors, such as use of indwelling catheters, lack of proper hygiene in the healthcare setting, and excessive use of antibiotics, can increase the risk of HAIs in patients. Thus, it is very crucial to disinfect all the devices used in healthcare settings.

The increasing number of ultrasound imaging procedures across the globe is anticipated to increase the product demand over the forecast period. According to the report published by the U.S. Department of Health & Human Services, on any given day, approximately one in 31 patients suffers from at least one HAI. Similarly, the WHO reported that out of every 100 patients on any given day, ten in developing countries and seven in developed countries acquire at least one HAI. Ultrasound probe disinfection eliminates the risk of transmission of any pathogen from one patient to another, which is anticipated to boost the demand over the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/ultrasound-probe-disinfection-market

Further key findings from the report suggest:

In terms of revenue, consumables are anticipated to witness the fastest growth over the forecast period as these are usually disposable and need to be bought frequently
Intermediate and low-level disinfection held the largest market share in 2019 and is anticipated to witness a significant growth rate over the forecast period
Hospitals and clinics end-use segment held the largest market share in 2019 owing to the rising number of ultrasound imaging procedures performed in these healthcare facilities
Asia Pacific is expected to be the fastest-growing regional market over the forecast period owing to the increasing usage of diagnostic imaging

Molecular Diagnostics Market Worth $18.2 Billion By 2027

The global molecular diagnostics market size is expected to reach USD 18.2 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 9.0% over the forecast period. Increasing prevalence of infectious diseases such as influenza and human papillomavirus is projected to be the key factor the growth of the market.

In the underdeveloped regions of Africa, increasing instances of infections such as tuberculosis and HIV have been witnessed in the last few years. This is projected to drive the demand for accurate and early diagnostic techniques to curb the spread of these infections.

Rapid technological advancements-leading to accurate results, portability, and cost-effectiveness-are expected to be a high impact rendering driver for this market. Companies are upgrading their products by implementing new techniques to gain specific and accurate results. Companies such as Sigma Aldrich Corporation and Qiagen are developing a new range of molecular diagnostic techniques, such as Transcription-Mediated Amplification (TMA) and Loop-Mediated Isothermal Amplification (LAMP), for the diagnosis of tumors.

Key players in the market are adopting various marketing strategies such as collaborations with technologically advanced companies and diagnostic centers. Furthermore, players are focusing on expanding their geographic presence in order to increase their market share.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/molecular-diagnostics-market

Further key findings from the report suggest:

Reagents dominated the market in 2019 and is also projected to be the fastest-growing product segment owing to its high adoption in research and clinical settings. Standard reagents also provide efficient and accurate results
Instruments such as next generation sequencing platforms and PCR are increasingly preferred by diagnostic institutes and central laboratories as these tests deliver reliable and quick results and are suitable for a number of diagnostic procedures
Central laboratories emerged as the leading test location for molecular diagnostics in 2019. This is attributed to the availability of skilled labor and well-established infrastructure
Point-of-care is expected to be the fastest-growing segment over the forecast period owing to increase in demand for bedside testing, accuracy of results, and rise in healthcare awareness
Infectious diseases were the largest revenue generating segment in 2019 as molecular diagnostics offer clinicians with better substitutes to diagnose numerous infectious pathogens, bacteria, and virus in a short time while producing extremely accurate results
The oncology segment is projected to exhibit a CAGR of around 11.3% over the forecast period owing to increasing awareness amongst patients and healthcare professionals regarding available technologies such as molecular testing for cancer diagnosis
On the basis of technology, PCR was the largest revenue generating segment in 2019 owing to factors such as growing applications of multiplex PCR and commercialization of easy-to-use PCR-based molecular diagnostic kits
North America was the largest revenue generating region in 2019, followed by Europe. Key factors attributing to their dominance are high patient awareness levels, sophisticated healthcare infrastructure, growing healthcare expenditure, and high R&D pertaining to drug discovery and development
Some of the major players operating in molecular diagnostics market are F. Hoffmann-La Roche Ltd; Siemens Healthcare GmbH; Bio-Rad Laboratories, Inc.; Novartis AG (Grifols); Danaher Corporation; Alere, Inc.; Sysmex Corporation; bioMérieux SA; Becton, Dickinson and Company; Hologic, Inc. (Gen Probe); Johnson & Johnson Services, Inc.; Bayer AG; Cepheid; Dako; and Qiagen.

Biological Safety Testing Products and Services Market Worth $6.9 Billion By 2026

The global biological safety testing products and services market size is expected to reach a value of USD 6.9 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 12.3% The market is predominantly driven by increasing production of biologics, which is boosting the need for highly efficient biological safety testing tools. Rising disease burden is expected to be a major factor responsible for high production of biologics, thereby contributing to market growth.

Increasing prevalence of lifestyle-associated chronic diseases such as cancer and diabetes is a key factor contributing to rise in drug development and subsequent commercialization. This is expected to increase the need for scrutinizing & ensuring safety of targeted and specialized therapies, evaluating outcomes, and circumventing probable shortcomings. In addition, pharmaceutical and biotechnology companies are increasingly incorporating biological safety testing products and services to produce highly potent and contamination-free biologics to cater to the large number of people suffering from target diseases. Viral safety testing is proving to be one of the primary concerns of most companies as it is a critical component of chemistry, manufacturing, and control of biologics. This is creating growth opportunities in the market.

Laboratory-based contamination is leading to development and refinement of workstations through incorporation of biological safety products and services. Increasing need to work with tissue cultures, maintain sterility of cell lines, and minimize cross-contamination has increased concerns regarding product integrity. Rising intervention by government healthcare organizations to implement good manufacturing practices and subsequent testing & control at every production stage is expected to widen the scope for growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/biological-safety-testing-market

Further key findings from the report suggest:

On the basis of product, reagents and kits accounted for the largest share in 2018 as they are major components that are extensively used in research and clinical laboratories
The instruments segment, on the other hand, is expected to grow at a lucrative CAGR during the forecast period due to rising demand from various clinical and research laboratories
On the basis of application, vaccines & therapeutics segment is expected to grow at a significant CAGR during the forecast period mainly owing to increase in disease outbreaks over the years
Bioburden tests are expected to grow at a lucrative rate during the forecast period owing to their high adoption to determine bioburden limit in a wide range of biologics and medical devices
North America dominated the global biological safety testing products and services market in 2018 owing to high R&D investments in biotechnology and huge chronic disease burden
Asia Pacific is expected to grow at an exponential CAGR during the forecast period owing to increase in healthcare spending
Some of the key players are Charles River Laboratories International, Inc.; Lonza Group AG; MilliporeSigma; SGS SA; Sartorius Stedim BioOutsource Limited; and BSL Bioservice Scientific Laboratories GmbH.

Molecular Diagnostics Market Worth $18.2 Billion By 2027

Click the link below:
https://www.grandviewresearch.com/industry-analysis/molecular-diagnostics-market

Further key findings from the study suggest:

Reagents dominated the market in 2019 and is also projected to be the fastest-growing product segment owing to its high adoption in research and clinical settings. Standard reagents also provide efficient and accurate results
Instruments such as next generation sequencing platforms and PCR are increasingly preferred by diagnostic institutes and central laboratories as these tests deliver reliable and quick results and are suitable for a number of diagnostic procedures
Central laboratories emerged as the leading test location for molecular diagnostics in 2019. This is attributed to the availability of skilled labor and well-established infrastructure
Point-of-care is expected to be the fastest-growing segment over the forecast period owing to increase in demand for bedside testing, accuracy of results, and rise in healthcare awareness
Infectious diseases were the largest revenue generating segment in 2019 as molecular diagnostics offer clinicians with better substitutes to diagnose numerous infectious pathogens, bacteria, and virus in a short time while producing extremely accurate results
The oncology segment is projected to exhibit a CAGR of around 11.3% over the forecast period owing to increasing awareness amongst patients and healthcare professionals regarding available technologies such as molecular testing for cancer diagnosis
On the basis of technology, PCR was the largest revenue generating segment in 2019 owing to factors such as growing applications of multiplex PCR and commercialization of easy-to-use PCR-based molecular diagnostic kits
North America was the largest revenue generating region in 2019, followed by Europe. Key factors attributing to their dominance are high patient awareness levels, sophisticated healthcare infrastructure, growing healthcare expenditure, and high R&D pertaining to drug discovery and development
Some of the major players operating in molecular diagnostics market are F. Hoffmann-La Roche Ltd; Siemens Healthcare GmbH; Bio-Rad Laboratories, Inc.; Novartis AG (Grifols); Danaher Corporation; Alere, Inc.; Sysmex Corporation; bioMérieux SA; Becton, Dickinson and Company; Hologic, Inc. (Gen Probe); Johnson & Johnson Services, Inc.; Bayer AG; Cepheid; Dako; and Qiagen.